Table 1.
Characteristics of RA patients for whom associations of single nucleotide polymorphisms with disease progression and response to therapy with TNF-α inhibitors were analyzed.
| RA Patients (N =) | 87 |
|---|---|
| Sex (female/male); n (%) | 71 (82%)/16 (18%) |
| Age (years) | 50.7 ± 12.3 (range: 17–77) |
| Females (%) | 71 (82%) |
| Disease duration (years) | 12.4 ± 8.3 (range 1–39) |
| Disease onset (years) | 38.8 ± 12.0 (range 15–65) |
| Current smokers (%) | 14 |
| RF+ Rheumatoid factor positive, n (%) | 72 |
| ACPA+/Anti-CCP present, n (%) | 47 |
| Stage, n (%) | |
| 1 | 2 (2.3%) |
| 2 | 20 (23%) |
| 3 | 51 (58.6%) |
| 4 | 14 (16.1%) |
| DAS28 at baseline | 6.59 ± 0.73 (range 5.14–8.05) |
| DAS28 at week 24 | 4.0 ± 1.12 (range 1.97–6.88) |
| anti-TNF drug | |
| etanercept (%) | 44 (50%) |
| adalimumab (%) | 32 (36%) |
| infliximab (%) | 7 (8%) |
| certolizumab pegol (%) | 5 (6%) |
| Glucocorticosteroids % | 79 (mean dose 9.3 mg prednisone daily) |
| Methotrexate % | 71 (mean dose 20.4 mg weekly) |
RA—rheumatoid arthritis, RF—rheumatoid factor, ACPA—anti-citrullinated protein antibodies, DAS 28—disease activity score 28, TNF—tumour necrosis factor.